Article Text
Community child health, public health, and epidemiology
Should recombinant human growth hormone therapy be used in short small for gestational age children?
Abstract
Short small for gestational age (SGA) children represent 20% of all children with short stature1 and therefore constitute a significant portion of the caseload in a growth clinic. The recent approval of recombinant human growth hormone (GH) for the treatment of short stature in SGA children by the European Union’s Committee on Proprietary Medicinal Products offers a new licensed therapeutic option. This article examines the role of GH therapy in short SGA children with particular reference to selection of patients, effectiveness, safety, and its potential metabolic implications.
- GH, growth hormone
- IGF, insulin-like growth factor
- IUGR, intrauterine growth retardation
- SGA, small for gestational age
- SGA
- growth hormone
- short stature
Statistics from Altmetric.com
Linked Articles
- Atoms